UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-39896 PLAYTIKA HOLDING CORP. (Exact Name of Registrant as Specified in its Charter) Delaware 81-3634591 (State of ...

Financial Performance - Revenues for Q3 2025 were $340.2 million, a 44.6% increase from $235.4 million in Q3 2024[205] - Net loss for Q3 2025 was $50.1 million, significantly improved from a net loss of $1,230.8 million in Q3 2024[205] - For the nine months ended September 30, 2025, revenues were $849.1 million, up from $705.2 million in the same period of 2024[206] - Revenues increased by $104.7 million, or 44.5%, in Q3 2025 compared to Q3 2024, primarily due to an increase in the number of inverters and power optimizers sold[229] - Revenues increased by $143.8 million, or 20.4%, in the nine months ended September 30, 2025, compared to the same period in 2024[234] - Net loss for the nine months ended September 30, 2025, was $273.3 million, down 82.0% from a net loss of $1,518.9 million in the same period of 2024[261] Profitability Metrics - Gross profit margin for Q3 2025 was 21.2%, compared to a gross loss margin of 309.1% in Q3 2024[205] - Gross profit for Q3 2025 was $72.1 million, compared to a gross loss of $727.8 million in Q3 2024[228] - Gross profit margin for the nine months ended September 30, 2025, was 14.3%, compared to a gross loss margin of 108.5% in the same period of 2024[206] - Gross profit as a percentage of revenue was 21.2% in the three months ended September 30, 2025, compared to a gross loss of 309.1% in the same period in 2024[240] Operational Changes - The company has discontinued its light commercial vehicle and energy storage divisions to focus on its core solar segment[201] - The company plans to remove certain key operating metrics, including inverters and power optimizers shipped, starting Q4 2025, in favor of metrics based on revenue recognized[222] - The company intends to simplify its product portfolio by reducing the variety of Stock Keeping Units (SKU), impacting the ability to track Megawatts shipped[223] Sales and Shipments - The company shipped approximately 140.0 million power optimizers and 6.1 million inverters as of September 30, 2025[204] - The number of power optimizers recognized as revenues increased by approximately 1.2 million units, or 67.1%, from approximately 1.8 million units in Q3 2024 to approximately 2.9 million units in Q3 2025[231] - The number of inverters recognized as revenues increased by approximately 38.5 thousand units, or 71.0%, from approximately 54.2 thousand units in Q3 2024 to approximately 92.7 thousand units in Q3 2025[231] - The number of power optimizers recognized as revenues increased by approximately 2.9 million units, or 59.4%, from approximately 4.8 million units to approximately 7.7 million units in the nine months ended September 30, 2025[236] - The number of inverters recognized as revenues increased by approximately 69.0 thousand units, or 37.9%, from approximately 181.9 thousand units to approximately 250.8 thousand units in the nine months ended September 30, 2025[236] Cost and Expenses - Cost of revenues decreased by $695.2 million, or 72.2%, in the three months ended September 30, 2025, compared to the same period in 2024[240] - Research and development costs decreased by $16.2 million, or 23.1%, in the three months ended September 30, 2025, compared to the same period in 2024[242] - Sales and marketing expenses decreased by $10.5 million, or 28.1%, in the three months ended September 30, 2025, compared to the same period in 2024[243] - General and administrative expenses decreased by $14.6 million, or 35.5%, in the three months ended September 30, 2025, compared to the same period in 2024[246] Cash Flow and Investments - Cash provided by operating activities was $51.6 million in the nine months ended September 30, 2025, compared to cash used of $351.1 million in the same period of 2024[264] - Cash provided by investing activities increased by $27.6 million in the nine months ended September 30, 2025, primarily due to a decrease in property plant and equipment purchases[266] - As of September 30, 2025, cash and cash equivalents were $439.5 million, excluding $59.1 million in marketable securities and $47.5 million in restricted cash[262] - The company has open commitments for capital expenditures of approximately $26.5 million, mainly for automated assembly lines and machinery[262] Customer Concentration - Two major customers accounted for approximately 40.1% of consolidated trade receivables as of September 30, 2025, up from 37.4% for three major customers in 2024[281] - One major customer represented approximately 23.1% of total revenues for the three months ended September 30, 2025, compared to 16.7% for the same period in 2024[281] - For the nine months ended September 30, 2025, two major customers accounted for approximately 32.4% of total revenues, compared to 11.0% for one major customer in 2024[281] Currency and Commodity Risks - The company is exposed to commodity price risk from fluctuating market prices of raw materials such as Copper, Lithium, Nickel, and Cobalt, which could impact operating margins[283] - The company does not enter into hedging arrangements to mitigate commodity risk, potentially harming financial condition and results of operations[283] - The company uses derivative financial instruments, including foreign currency forward contracts, to manage exposure to foreign currency risks[279] - As of September 30, 2025, the company’s consolidated results are subject to fluctuations due to changes in foreign currency exchange rates[278] - A hypothetical 10% change in foreign currency exchange rates between the Euro and the U.S. dollar would increase or decrease net income by $12.8 million for the nine months ended September 30, 2025[277] - A hypothetical 10% change in foreign currency exchange rates between NIS and the U.S. dollar would increase or decrease net income by $4.5 million for the nine months ended September 30, 2025[277]

Financial Performance - Net income for Q3 2025 was $18.4 million, a decrease of 71.5% from $64.6 million in Q3 2024[2] - Earnings per share (EPS) from continuing operations for Q3 2025 was $0.09, compared to $0.08 in Q3 2024, reflecting a 12.5% increase[2] - Income from continuing operations increased by $2.8 million year-over-year, totaling $18.4 million in Q3 2025[3] - The electric utility segment reported a net income of $21.5 million in Q3 2025, down from $24.3 million in Q3 2024, primarily due to higher operation and maintenance expenses[4] - For Q3 2025, the company reported a net loss of $1.7 million, a significant decrease from a net income of $42.7 million in Q3 2024, primarily due to the absence of income from discontinued operations[28] - The loss from continuing operations for Q3 2025 was $1.7 million, a 73.0% improvement from a loss of $6.3 million in Q3 2024[27] Revenue and Expenses - Operating revenues for Q3 2025 were $315.1 million, an increase of 8.5% from $289.6 million in Q3 2024[17] - The electric business reported operating revenues of $117.8 million for Q3 2025, an increase of 8.6% compared to $108.5 million in Q3 2024[21] - Natural gas distribution operating revenues increased to $144.3 million in Q3 2025, an 8.0% rise from $133.6 million in Q3 2024[23] - Pipeline operating revenues reached $57.4 million in Q3 2025, an increase of 11.5% from $51.5 million in Q3 2024[25] - Total operating expenses for the electric segment increased by 17.0% to $89.4 million in Q3 2025, compared to $76.4 million in Q3 2024[21] - The natural gas distribution segment's total operating expenses increased by 7.4% to $159.3 million in Q3 2025, compared to $148.3 million in Q3 2024[23] - The pipeline segment's total operating expenses rose by 11.6% to $32.8 million in Q3 2025, compared to $29.4 million in Q3 2024[25] Capital Expenditures and Guidance - Total capital expenditures for 2025 are estimated at $531 million, with $294 million allocated to natural gas distribution[19] - The company narrowed its earnings guidance for 2025 to a range of $0.90 to $0.95 per share, reflecting performance through Q3[9] Customer Growth - Natural gas retail customer count increased by 1.6% year-over-year, indicating growth in the customer base[7] Business Segments Performance - The pipeline segment reported a net income of $16.8 million in Q3 2025, up 11.3% from $15.1 million in Q3 2024[8] - The natural gas distribution segment reported a seasonal loss of $18.2 million in Q3 2025, compared to a loss of $17.5 million in Q3 2024, driven by higher operation and maintenance expenses[24] - Net income for the electric segment decreased to $21.5 million in Q3 2025, down 11.5% from $24.3 million in Q3 2024, primarily due to higher operation and maintenance expenses[22] Operational Improvements - The operating income for Q3 2025 was $1.8 million, a turnaround from an operating loss of $4.7 million in Q3 2024, reflecting a 138.3% improvement[27] - The company experienced a 61.0% reduction in interest expense, which decreased to $1.6 million from $4.1 million year-over-year[27] Tax and Valuation - The income tax expense for Q3 2025 was $3.9 million, reflecting a 129.4% increase compared to $1.7 million in Q3 2024[27] - The book value per common share as of September 30, 2025, was $13.33, while the market price per common share was $17.81, resulting in a market value of 133.6% of book value[30] - Total assets as of September 30, 2025, amounted to $7,186 million, with total equity at $2,723 million and total debt at $2,353 million[30] - The company's capitalization ratios indicated that total equity comprised 53.6% of the capital structure, while total debt accounted for 46.4%[30] Corporate Developments - The company completed the separation of its former construction services business, Everus, into a new independent publicly-traded company on October 31, 2024[27] - The company is actively pursuing expansion projects, including the Line Section 32 Expansion Project and the Minot Industrial Pipeline Project, to enhance service capacity[10]

Financial Position - As of September 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $615.9 million[107] - Cash, cash equivalents, and marketable securities as of September 30, 2025, totaled $615.9 million, up from $489.9 million as of December 31, 2024[150] - The accumulated deficit as of September 30, 2025, was $449.7 million, reflecting ongoing operational losses since inception[132] - The company has contractual lease commitments totaling $3.34 million, with payments due over the next five years[143] - Interest income primarily consists of earnings from cash equivalents and marketable securities, contributing to the company's financial operations[117] Revenue and Losses - The company has not generated any revenue since inception and does not expect to do so in the near future[108] - Net loss for Q3 2025 was $62.3 million, compared to a net loss of $26.6 million in Q3 2024, reflecting a 134% increase in losses year-over-year[119] - Total operating expenses for Q3 2025 reached $67.7 million, up 106% from $32.9 million in Q3 2024, leading to a loss from operations of $67.7 million compared to a loss of $32.9 million in the same period last year[119] - The company expects to continue incurring significant operating losses and may require additional capital to fund operations, potentially through equity or debt financing[128][129] Expenses - Research and development expenses for Q3 2025 were $50.3 million, a 103% increase from $24.7 million in Q3 2024, primarily due to increased costs in clinical trials and personnel-related expenses[120][122] - Selling, general and administrative expenses for Q3 2025 were $17.4 million, a 113% increase from $8.2 million in Q3 2024, driven by higher personnel-related costs and professional fees[123][124] - Selling, general and administrative expenses are expected to increase significantly as the company expands its workforce and infrastructure for potential commercialization[116] - The company anticipates substantial increases in research and development expenses as clinical programs advance[112] Clinical Development - Bitopertin, the lead product candidate, has shown significant reduction in protoporphyrin IX (PPIX) levels and improvements in quality of life in clinical trials[103] - The FDA agreed that PPIX reduction could serve as a surrogate endpoint for accelerated approval of bitopertin in EPP and XLP[103] - DISC-0974 demonstrated substantial decreases in hepcidin and increases in iron levels in a Phase 1b study for anemia of myelofibrosis[105] - The company plans to initiate a Phase 2 clinical trial of DISC-0974 in patients with inflammatory bowel disease and anemia in Q1 2026[105] - The company expects substantial increases in expenses as it advances product candidates through clinical development, necessitating additional funding[140] Financing Activities - In October 2025, the company completed a public offering for net proceeds of approximately $210.9 million, which will fund operations into 2029[107] - In October 2025, the company completed a public offering that generated net proceeds of approximately $210.9 million, enhancing its capital resources[131] - Net cash provided by financing activities increased to $256.7 million in the nine months ended September 30, 2025, from $189.5 million in the same period of 2024[138][139] - Future funding may come from equity offerings, debt financings, collaborations, and licensing arrangements, but there is a risk of dilution for existing stockholders[141] Cash Flow - Net cash used in operating activities for the nine months ended September 30, 2025, was $137.1 million, significantly higher than $66.4 million for the same period in 2024, indicating increased operational expenditures[133][135] - Net cash used in investing activities for the nine months ended September 30, 2025, was $491.3 million, compared to $313.9 million for the same period in 2024[137][138] Market and Economic Factors - If market interest rates increase by one percentage point, the net fair value of marketable securities would decrease by approximately $2.6 million[150] - Inflation has not had a material effect on the company's financial condition or results of operations during the nine months ended September 30, 2025[152] - The company has minimal exposure to foreign currency risk due to the short duration of transactions[151] - There are no material changes to critical accounting estimates from the previous year, indicating stability in financial reporting[147]

Revenue Growth - Direct title revenues increased to $299,690,000 in Q3 2025 from $270,706,000 in Q3 2024, representing a growth of 10.5%[10] - Agency title revenues rose to $360,186,000 in Q3 2025 compared to $282,549,000 in Q3 2024, marking a significant increase of 27.5%[10] - Operating revenues for the nine months ended September 30, 2025, reached $2,077,954,000, up from $1,772,416,000 in the same period of 2024, reflecting a growth of 17.2%[10] - Total operating revenues for the nine months ended September 30, 2025, reached $2.078 billion, up 17.2% from $1.772 billion in the same period of 2024[24] - Consolidated operating revenues for Q3 2025 were $776.5 million, an increase of $126.9 million, or 20%, compared to the prior year quarter[51] - The title segment generated revenues of $678.9 million in Q3 2025, a 19% increase from $571.6 million in Q3 2024, driven by a $106.6 million increase in operating revenues[47][52] - The real estate solutions segment's revenues increased by 21% to $116.6 million in Q3 2025, compared to $96.4 million in Q3 2024[55][56] - Total revenues from U.S. operations were $747.4 million in Q3 2025, up from $629.0 million in Q3 2024, reflecting a 19% increase[49] Net Income and Earnings - Net income attributable to Stewart increased to $44,259,000 in Q3 2025, compared to $30,096,000 in Q3 2024, a rise of 47.1%[10] - Basic earnings per share attributable to Stewart improved to $1.58 in Q3 2025 from $1.09 in Q3 2024, an increase of 45%[10] - Net income attributable to Stewart for the nine months ended September 30, 2025, was $79.258 million, compared to $50.569 million for the same period in 2024, representing a 56.8% increase[14] - The company reported net income of $44.3 million ($1.55 per diluted share) for Q3 2025, up from $30.1 million ($1.07 per diluted share) in Q3 2024, representing a 47% increase in net income[51] Cash Flow and Investments - Cash provided by operating activities for the nine months ended September 30, 2025, was $116,146,000, compared to $67,656,000 in the same period of 2024, indicating a growth of 71.7%[13] - Cash and cash equivalents at the end of Q3 2025 were $188,518,000, a decrease from $216,298,000 at the beginning of the period[13] - Cash claim payments increased by $1.5 million (8%) in Q3 2025 compared to the prior year quarter, while decreasing by $13.0 million (19%) in the first nine months of 2025[87] - Cash flows from operations and cash available from underwriters are expected to be sufficient to fund operations, including claims payments, despite potential needs for additional debt or equity funding[105] Equity and Stockholder Information - Total stockholders' equity attributable to Stewart increased to $1,473,418,000 as of September 30, 2025, from $1,402,142,000 at the end of 2024, a rise of 5.1%[12] - The balance of total equity as of September 30, 2025, was $1.482 billion, an increase from $1.414 billion as of September 30, 2024[16] - The company declared dividends on common stock of $1.53 per share for the nine months ended September 30, 2025, compared to $1.45 per share in 2024[14] - Total dividends paid increased to $42.6 million ($1.53 per common share) in the first nine months of 2025, compared to $40.0 million ($1.45 per common share) in the same period of 2024[104] Expenses and Losses - The company experienced an increase in estimated title losses to $520,445,000 as of September 30, 2025, compared to $511,534,000 at the end of 2024[12] - Title loss expense decreased by $1.7 million (8%) in Q3 2025, with the loss expense as a percentage of title operating revenues improving to 3.0% from 3.8% in Q3 2024[53] - Consolidated other operating expenses increased by $29.5 million (19%) in Q3 2025 and $74.7 million (17%) in the first nine months of 2025 compared to the same periods in 2024[82] - Provisions for title losses improved to 3.0% of title operating revenues in Q3 2025, down from 3.8% in Q3 2024, with total title loss expense decreasing by $1.7 million (8%) in Q3 2025[84] Employee and Operational Metrics - Employee costs in the title segment increased by $27.0 million (10%) in Q3 2025, attributed to higher salaries and increased employee count[52] - Consolidated employee costs rose by $17.4 million (9%) in Q3 2025 and $59.3 million (11%) in the first nine months of 2025 compared to the same periods in 2024, primarily due to higher salaries and benefits[78] - The average employee count increased by 9% in Q3 2025 compared to Q3 2024, with approximately 7,400 employees[79] - Total employee costs as a percentage of total operating revenues improved to 27.2% in Q3 2025 from 29.8% in Q3 2024, reflecting higher operating revenues[79] Debt and Financing - The company entered into a new senior unsecured credit agreement providing a $300 million revolving credit facility maturing in October 2030[23] - Total debt and stockholders' equity were $446.1 million and $1.48 billion, respectively, as of September 30, 2025, with improved debt-to-equity and debt-to-capitalization ratios of approximately 30% and 23% compared to 32% and 24% at December 31, 2024[103] Market and Economic Conditions - Total U.S. single-family mortgage originations in Q3 2025 were $518 billion, a 14% increase compared to Q3 2024, with refinancing transactions growing by 46%[65] - Existing home sales in September 2025 were approximately 4.06 million units, a 4% increase from September 2024, attributed to falling mortgage rates[64] - The average 30-year fixed mortgage interest rate was 6.6% in Q3 2025, slightly improved from 6.8% in Q2 2025[65] - The unsold home inventory in the U.S. was 1.55 million units as of September 2025, a 14% increase compared to the previous year[64]

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Steve Jones Mary M. Gentry Senior EVP, Chief Financial Officer SVP, Finance and Treasurer ScanSource, Inc. ScanSource, Inc. (864) 286-4302 (864) 286-4892 SCANSOURCE REPORTS FIRST QUARTER RESULTS Achieves Double-Digit EPS Growth and Strong Q1 Free Cash Flow GREENVILLE, SC -- November 6, 2025 -- ScanSource, Inc. (NASDAQ: SCSC), a leading technology distributor uniquely positioned to address complex, converging technologies, today announced financial results for the ...

Exhibit 99.1 Management's discussion and analysis Table of contents | 1 Overview | 7 | | --- | --- | | 1.1 Financial highlights | 7 | | 1.2 Key corporate and business developments | 9 | | 1.3 Assumptions | 11 | | 2 Consolidated financial analysis | 12 | | 2.1 BCE consolidated income statements | 12 | | 2.2 Customer connections | 13 | | 2.3 Operating revenues | 15 | | 2.4 Operating costs | 16 | | 2.5 Net earnings (loss) | 17 | | 2.6 Adjusted EBITDA | 18 | | 2.7 Severance, acquisition and other costs | 19 | | ...

Drug Development and Regulatory Approvals - Bitopertin has been selected for the FDA's Commissioner's National Priority Voucher (CNPV) Pilot Program, which offers accelerated reviews for drug applications, with an anticipated review period of 1-2 months[7]. - The NDA for Bitopertin was submitted on September 29, 2025, with FDA acceptance expected on or before November 28, 2025[7]. - The company is advancing commercial readiness activities to support the potential launch of Bitopertin on an accelerated timeline, if approved[7]. - The ongoing APOLLO confirmatory trial aims to support potential US approval and launch of Bitopertin in late 2025 or early 2026[57]. - Positive data across two Phase 2 studies support the durability of efficacy, with potential approval anticipated late 2025 to early 2026[175]. - NDA submitted on September 29, 2025, with a designed review time of 1-2 months[175]. - Initial data from the RALLY-MF Phase 2 study in MF anemia is expected soon, alongside the initiation of a Phase 2 study in IBD anemia anticipated in Q1 2026[175]. Clinical Trials and Study Results - The APOLLO study for EPP is currently underway, with a confirmatory trial required for full approval in the US[44]. - The anticipated initiation of the Phase 2 study for Anemia of Inflammatory Bowel Disease (IBD) is expected in Q1 2026[20]. - The Phase 2 trial for Bitopertin in Diamond Blackfan Anemia is currently underway, sponsored by NIH[61]. - The study enrolled a total of 35 participants, with 32 (91%) completing the study[95]. - 54% of participants receiving concomitant JAK inhibitor therapy achieved a major hematologic response[105]. - A significant 66% of patients experienced an increase in hemoglobin of at least 1.5 g/dL during the treatment period[101]. - The overall response rate for any hemoglobin increase of ≥1.5 g/dL was 68%[101]. - The study demonstrated a 43% reduction in erythropoietin levels and a 29% reduction in ferritin levels from baseline among major responders[108]. - Safety profile indicated that 94.1% of participants experienced any treatment-emergent adverse events (TEAEs), with most being Grade 1 or 2[112]. - The ongoing RALLY-MF Phase 2 study is assessing options for the NDD-CKD anemia program[175]. - A Phase 1b study for Sickle Cell Disease is expected to be initiated by the end of the year[172]. - The study design includes dose escalation and safety follow-up for Sickle Cell Disease participants[173]. Patient Populations and Disease Impact - The Erythropoietic Protoporphyria (EPP) patient population is estimated at approximately 20,000 in the US, with around 6,000 diagnosed patients actively seeking treatment[32]. - Real-world data indicates that 56% of EPP patients experience anxiety and/or depression, highlighting the significant impact of the disease on quality of life[35]. - Anemia remains a high unmet need within the myelofibrosis patient population, with approximately 22,000 addressable patients in the US[120]. - Approximately 5 to 6 million anemic non-dialysis dependent chronic kidney disease (NDD-CKD) patients in the US, with hepcidin levels ~20 times higher than healthy subjects[122]. - The estimated number of myelofibrosis patients in the US is 25,000, with around 87% experiencing anemia[94]. Pipeline and Future Studies - The pipeline includes multiple programs targeting hematologic diseases, with significant potential for addressing severe and moderate prevalence conditions[18]. - The company plans to initiate a Phase 2 study in IBD patients with anemia in Q1 2026[90]. - The company plans to initiate a Phase 2 study in patients with inflammatory bowel disease (IBD) and anemia in 2026[134]. - Phase 1 studies for DISC-3405 in healthy volunteers began in October 2023, assessing safety, pharmacokinetics, and hematologic parameters[154]. - The company is exploring other indications for DISC-3405, including hereditary hemochromatosis and beta-thalassemia[154]. Treatment Efficacy and Safety - Bitopertin 60 mg demonstrated a significant 40% reduction in PPIX levels compared to baseline after 6 months of treatment[48]. - Patients experienced a 75% reduction in the rate of phototoxic reactions versus placebo, with 86% reporting that their condition was 'much better'[48]. - The average cumulative total time in sunlight without pain increased significantly, with patients in the highest tertile experiencing 262.1 hours[52]. - Nearly all participants in the HELIOS study reported substantial improvements in quality of life measures through week 24[56]. - DISC-0974, an anti-HJV mAb, is designed to enhance iron availability and address a wide range of hematologic disorders[75]. - Hepcidin levels in myelofibrosis patients are approximately 12 times higher than controls, correlating with anemia severity[93]. - DISC-0974 demonstrated a 1.7 g/dL increase in hemoglobin levels compared to the vehicle control in a rat model of CKD[127]. - DISC-0974 resulted in a substantial, durable, dose-dependent reduction in hepcidin and sustained increase in transferrin saturation (TSAT) from baseline[129]. - DISC-3405 achieved ~70% suppression of serum iron levels lasting for 3 weeks in non-human primates[145]. - DISC-3405 produced dose-related increases in serum hepcidin, with corresponding reductions in serum iron ranging from 50-80% from baseline[161]. - The study showed consistent decreases in hepcidin and increases in serum iron across patients[99]. - DISC-3405 demonstrated meaningful reductions in hematologic parameters, including reticulocyte hemoglobin and hematocrit, in healthy volunteers[162]. - DISC-3405 resulted in an average 94% reduction in iron absorption at Day 2 and 68% at Day 15, confirming its mechanism to block dietary iron absorption[171].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission File Number: 000-26926 ScanSource, Inc. (Exact name of registrant as specified in its charter) South Carolina 57-0965380 (State or other juri ...

Exhibit 99.1 "We had a strong quarter, driven by a rebound in farming and steady results across our core operating segments," said Matthew Walker, president and CEO of Tejon Ranch Company. "Farming delivered an approximately $2 million positive variance from the prior year, helping year-to-date earnings recover. "As part of our comprehensive review of cost structure and capital allocation, we've taken decisive steps to reduce expenses, including a 20 percent reduction in our workforce. This difficult but ne ...